疫苗

These stimuli-switchable nanoparticles coated with the cleavable outer polymer coatingmultifunctional peptides may afford a new platform for anticancer drugmiR. These nanoparticles possess characteristics of environmental response, active targeting,gene/chemo combinatorial therapeutics, thus providing spatiotemporal control of posttranｓｃｒｉｐｔional gene regulation, smart nuclear/mitochondrial localization,simultaneous inhibition of multiple progression pathways of tumor cells for enhancing antitumor efficacysafety of cancer therapy.

Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.

Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.

Monoglycosylated spike protein vaccine provides better protection against infections of SARS-CoV-2its variants of concern. Spike protein, which is the main immunogen in all current vaccines, is heavily glycosylatedthe epitopes covered by glycans are usually less immunogenic. Monoglycosylated spike protein vaccine, when vaccinated, can elicit better immune response with a more complete protection against all possible epitopes from spike polypeptide sequence,provide better protection against infections from variants of concerns.

We developed a chicken mucosa-targeting polymeric nanoparticle vaccine (~90 nm) co-delivering viral antigenCpG adjuvant using a water-in-oil-in-water double emulsion technique. The particles are biodegradablebiocompatible. This nanoparticle significantly stimulated chicken Harderian gland B cell proliferationsubsequent local IgAIgG secretion in tears. The mucosal Ig protected chickens from virus infection by lowering virus replication at the infection sitethereafter reducing tracheal epithelial ciliostasissystemic infection, relieving clinical symptoms.

Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.

Vaccination is the most effective way to prevent influenza viruses infection. The egg-based production method has many drawbacks, we established baculovirus-based VLPs expression platform for H7N9 VLPs production, purify the VLPs satisfied with FDA regulation,improved its immunogenicity to the same level compared with H7N9 whole virus vaccine.

The invention provides a glycan-masking and/or glycan-unmasking hemagglutinin, wherein the glycosylation site(s) is added on globular headremoved on stem. The glycan-masking and/or glycan-unmasking hemagglutinin may induce neutralizing antibody against influenza virus,cross-reactive protection against different virus. The invention also provides a method for manufacturing these antigens.

Provided is an influenza mucosal vaccine compositionpreparationapplication thereof. This composition contains an antigen fusion protein which includes an influenza virus antigena Type IIb heat-labile enterotoxin A subunit. Immunization with the antigen fusion protein induces cellularhumoral immune responses, including systemicmucosal immune responses, against a specific in

We developed a recombinant adenovirus Ad-HFMD vaccine which can express virus-like particles (VLPs) of EV71 capsid proteins. Mouse studies showed that Ad-HFMD can induce the protective antibodycellular immunity against EV71CVA16 in hSCARB2 transgenic (hSCARB2-Tg) mouse challenge model.

In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.

Our present invention firstly provides a new ultrasound (US)-multifunctional microbubble (MB) which can be applied to a topical region of the body surface of organisms by applyingsputtering, instead of using injection. Some interesting topics have been explored: 1. US-aided MBs facilitate the delivery of drugs to the inner ear via the transcanal method, 2. drug-carrying modified MB combine wit

The "Viral Vaccine Cell Production Technology Platform" of this exhibition is based on 1. Host cell and virus match and colonization technology; 2. Cell-expressed virus receptor technology; 3. Blocking antiviral mechanism of host cell; 4. Immortalization technology of host cell; 5. Serum-free suspension cell culture technology to produce high-immunity virus vaccine strains containing intact virus antigens.

The National Center for High-performance Computing (NCHC) of the National Applied Research Laboratories uses API (application programming interface) to connect public data from Johns Hopkins UniversityTaiwan＇s Ministry of HealthWelfare. That means when raw data updated, the website will also automatically update its numbers. The purpose is to let people discuss in a scientificobjective waydata could be verified a step further.

A method of enhancing a mammalian immune response to a virus is disclosed. The method comprises administering a composition comprising an effective amount of epinecidin (Epi)-1the virus to a mammal, wherein the virus has envelope proteinis infectious to the mammal. In this technique, Epi-1Japanese encephalitis virus (JEV) were mixedinjected into mice. The mice were infected with JEV 14 days later,all mice survived. This technology has also been verified in the preparation of vaccines for foot-and-mouth disease virusnervous necrosis virus.

Our core generated several types of transgenic micea stable humanized ACE2 mice using a combi-CRISPR genetic engineering technique. We hope these mouse models can help to dissect COVID-19 pathogenic mechanismthe interaction(s) between spike proteinACE2 K353.

“Aerogel Cold Chain Storage Box with High-efficiency Thermal Insulation Performance” insulation layer includes phase change materials aerogel phenolic foamed insulation materials,aerogel insulation coatings. The carbon fibre used composite materials as the box shell. It is an innovative vaccine mobile refrigerator that does not require a power supply. It can keep cold for a long timehas good low-temperature stability. Our thermal materials have better cold retentionfire resistance than the insulation material used in the international COVID-19 vaccine storage.

With the use of E. coli expression system, capsid protein assembly in vitro, X-ray photoprotein crystallographycryo-electron microscope, the T=3 capsid structure of white tail disease viruses for shrimps has been resolved successfully, such that an entire model for capsid structure of virus could be provideda mechanism for viral assemblyinfection could be understood.